



## An open label single arm clinical study to evaluate the combined effect of Dashamoola Ksheera Basti and Rakta Chandana Yoga oral administration in Vandhyatwa w.s.r. to Female Infertility

Bhat PD<sup>1\*</sup>, Mamtha KV<sup>2</sup>

DOI:10.21760/jaims.10.2.7

<sup>1\*</sup> P Deepika Bhat, Final Year Post Graduate Scholar, Dept of Prasuti Tantra and Stree Roga, Shri Dharmasthala Manjunatheshwara College of Ayurveda, Udupi, Karnataka, India.

<sup>2</sup> Mamtha KV, Professor and Principal, Shri Dharmasthala Manjunatheshwara College of Ayurveda, Udupi, Karnataka, India.

Infertility is a global crisis that affects millions across the world. Infertility is the failure to achieve conception by a couple of mature age, having normal coitus, during appropriate period of menstrual cycle, regularly at least for one year.[1] It affects approximately 12-15% of couples of reproductive age globally.[2] Increasing incidence of infertility demands more energetic Ayurvedic approaches. So, aiming at finding out the best method of treatment for Infertility, this study is taken up to evaluate the combined effect of Dashamoola Ksheera Niruha Basti and Rakthachandana Yoga oral administration on 20 patients of female infertility selected from OPD and IPD of Shree Dharmasthala Manjunatheshwara Ayurveda Hospital, Udupi and clinical assessment was done on the basis of subjective and objective criteria. Statistically and clinically significant results were obtained.

**Keywords:** Dashamoola Ksheera Basti, Rakta Chandana Yoga, Vandhyatwa, Female Infertility

Corresponding Author	How to Cite this Article	To Browse
P Deepika Bhat, Final Year Post Graduate Scholar, Dept of Prasuti Tantra and Stree Roga, Shri Dharmasthala Manjunatheshwara College of Ayurveda, Udupi, Karnataka, India. Email: <a href="mailto:pdeepikabhat@gmail.com">pdeepikabhat@gmail.com</a>	Bhat PD, Mamtha KV, An open label single arm clinical study to evaluate the combined effect of Dashamoola Ksheera Basti and Rakta Chandana Yoga oral administration in Vandhyatwa w.s.r. to Female Infertility. J Ayu Int Med Sci. 2025;2(10):43-48. Available From <a href="https://jaims.in/jaims/article/view/4201">https://jaims.in/jaims/article/view/4201</a>	

Manuscript Received  
2025-01-17

Review Round 1  
2025-01-25

Review Round 2  
2025-02-04

Review Round 3  
2025-02-14

Accepted  
2025-02-22

Conflict of Interest  
None

Funding  
Nil

Ethical Approval  
Yes

Plagiarism X-checker  
12.52

Note



© 2025 by Bhat PD, Mamtha KV and Published by Maharshi Charaka Ayurveda Organization. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License <https://creativecommons.org/licenses/by/4.0/> unported [CC BY 4.0].



## Introduction

Parenthood is often celebrated as a profound and joyous journey, with the arrival of a new life as one of the nature's most miraculous. Traditionally, marriage has been closely linked with the expectation of procreation and family life; therefore, infertility becomes a particularly complex issue that intertwines personal distress with societal expectations.

Infertility, when viewed from both modern and Ayurvedic perspectives, reveals distinct yet complementary insights. Infertility is defined as the inability to conceive after one year of unprotected sexual intercourse. Female infertility can be caused by various factors like- cervical, uterine, tubal and ovarian factors. Though the explanation of infertility is available in other Samhitas, particularly in the *Harita Samhita*, a detailed explanation of *Vandyatwa* (infertility) and its subtypes is provided. [3]

In classics, *Vandyatwa* is often considered a complication arising from untreated conditions such as *Yonivyapat* (gynaecological disorders), *Artavavyapat* (menstrual disorders), and *Asrigdhara* (abnormalities in menstruation), and is classified as one of the 80 *Vataja Nanatmaja Vikaras* (diseases caused by *Vata* imbalance). [4]

*Vata Dosha* plays a pivotal role in the pathology of all *Yonivyapat* and *Artavavyapat*. [5] *Basti*, being *Ardha Chikitsa*, [6] which is said to be *Paramaushadha* for treatment of *Vata* disorders, [7] tackles all the gynecological pathologies of *Vata* including *Vandhyatwa*. *Sahacharadi Taila* is selected for *Anuvasna Basti*.

As *Sahachara* is a potent *Vatahara* drug [8] and *Taila* does *Yoni Vishodhana*. [9] *Dashamoola* is best *Vata Kaphahara*. *Ksheera* is *Amritopama*. [10]

When *Dashamoola* is processed with *Ksheera*, it acts best on *Tridosha*. *Dashamoola Ksheera Niruha Basti* is thus preferred. *Raktachandana* is *Vrishya* [11] and *Apamarga* is *Vatahara*. So, in this clinical trial oral administration of *Raktachandana* with *Apamarga Swarasa* has been taken.

## Materials and Methods

**Ethical Clearance:** Clearance from the Institutional Ethical Committee was obtained.

**Sample source:** A minimum of 20 subjects who have been unable to conceive and fulfilling the diagnostic criteria were selected for study from OPD and IPD of Sri Dharmasthala Manjunatheswara Ayurveda Hospital, Kuthpady, Udupi.

**Consent:** A written consent was taken from the patients before their participation in the trial.

**Drug source:** *Sahacharadi Taila*, *Raktachandana Churna* and the drugs for *Niruha Basti* were procured from SDM Pharmacy, Udupi.

*Apamarga* (*Achyranthes aspera* Linn.) identified and collected from their natural habitat.

### Inclusion Criteria:

1. Patients of Primary infertility and secondary infertility, aged between 19-40 years.
2. Patient who is in active marital life with partner having normal seminogram.
3. Patients who are fit for
4. Patients with Unexplained Infertility.

### Exclusion Criteria:

1. Patients with Genital infections.
2. Patients with Bad obstetric history (Previous unfavorable fetal outcome in terms of 2 or more consecutive spontaneous abortions, early neonatal deaths, etc.)
3. Patients with premature ovarian failure.
4. Patients with Congenital anomalies of uterus.
5. Patients with surgical factors including uterine fibroids, cervical polyp, pin hole cervical os etc.
6. Patients suffering from genital tuberculosis.
7. Patients with hydrosalpinx and tubal block.
8. Patients with Sexually Transmitted Diseases such as HIV and HBsAg.
9. Any other systemic illness such as DM, HTN, Thyroid dysfunction.

### Intervention:

1. *Dashamoola Ksheera Basti* and *Sahacharadi Taila Anuvasana Basti* in *Yoga Basti* course, after cessation of menstrual bleeding for 2 consecutive menstrual cycles.
2. Combination of *Raktachandana Churna* - 5 grams and *Apamarga Swarasa* - 10 ml, before food BD for 8 days, after cessation of menstrual bleeding for 2 consecutive menstrual cycles (No other interventions will be done till the follow-up of the subject)

### Poorvakarma:

#### Preparation of the medicine:

#### Ingredients:

Preparation of *Ksheerapaka* - 125 gm of *Kashaya* drugs is taken. To this 1000 ml of water and 250 ml of *Godugdha* is added and boiled till it is reduced to 250 ml.

*Madhu* - 80 ml

*Saindhava Lavana* - 5 gm

*Moorchita Tila Taila* - 120 ML

*Dashamoola Kalka* - 40 gm

*Dashamoola Ksheerapaka* - 250 ml

Total - 480 ML

#### Preparation of the patient:

- *Sthanika Abhyanga* to abdomen and buttock with *Murchitha Tila Taila* with *Ushna Jala*
- *Sthanika Swedana* to abdomen and buttocks by *Nadi Sweda*
- Patient will be on empty stomach for *Niruha Basti* and consume food before the administration of *Anuvasana Basti*

### Pradhana Karma:

*Niruha* and *Anusavasana Basti* were administered as per *Basti* guidelines.

#### Duration:

- Duration of treatment - Two Consecutive cycles - 16 days
- Follow-up - After 2 months
- Total duration of study - 2 Months

#### Assessment Criteria:

Patient was evaluated before (0th day), at the end of the second course of *Basti* and oral medication and on the day of follow up, based on subjective and objective parameters.

#### Subjective Parameters:

Attainment of *Suddha Artava Lakshanas*.

#### Objective Parameters:

Conception evidenced by UPT and USG.

- Conceived
- Not conceived

## Observation and Results

### 1. Colour of bleeding

**Table 1: Showing the mean of Colour of bleeding.**

BT Mean	Mean	Diff D	%	Wilcoxon rank test				
				SD	SEM	P	Z	Significance
1.600	AT 1.150	0.45	28.125	BT 0.821	0.184	0.016	-2.460	S
				AT 0.489	0.109	1.000	0.000	S
	FU 1.150	0.45	28.125	FU 0.489	0.109	0.031	-2.251	S

The initial mean score for Colour of bleeding was 1.600, which decreased to 1.150 after treatment and 1.150 after follow-up. This reflects a mean difference of 0.45, after treatment and follow-up, indicating improvements of 28.125%. Additionally, tests for statistical significance confirm that these results are statistically significant, with p-values of 0.016, demonstrating a definite therapeutic benefit of the treatment on Colour of bleeding.

### 2. CLOTS

**Table 2: Showing the mean of clots**

BT Mean	Mean	DiffD	%	Wilcoxon rank test				
				SD	SEM	P	Z	Significance
0.500	AT 0.150	0.35	23.3	BT 0.513	0.115	0.039	2.333	S
				AT 0.366	0.0819	0.002	-3.162	S
	FU 0.000	0.5	33.33	FU 0.000	0.000	0.002	-3.162	S

The initial mean score for Clots was 1.500, which decreased to 0.150 after treatment and further to 0.000 after follow-up. This reflects a mean difference of 0.35 and 0.5, respectively, after treatment and follow-up, indicating improvements of 23.3% and 33.33%. Additionally, tests for statistical significance confirm that these results are statistically significant, with p-values of 0.039 and 0.002, demonstrating a definite therapeutic benefit of the treatment on Clots of Menstrual bleeding.

### 3. Dysmenorrhea

**Table 3: Showing the mean of dysmenorrhea**

BT Mean	Mean	DiffD	%	Wilcoxon rank test				
				SD	SEM	P	Z	Significance
2.500	AT 1.350	1.15	46	BT 1.000	0.224	<0.001	-3.360	S
				AT 0.489	0.109	0.031	-2.449	S
	FU 1.050	1.45	58	FU 0.224	0.0500	<0.001	-3.568	S

The initial mean score for Dysmenorrhea was 2.500, which decreased to 1.350 after treatment and further to 1.050 after follow-up.

This reflects mean difference of 1.15 & 1.45, respectively, after treatment & follow-up, indicating improvements of 46% & 58%. Additionally, tests for statistical significance confirm that these results are statistically significant, with p-values of <0.001, demonstrating definite therapeutic benefit of treatment on dysmenorrhea.

#### 4. Dyspareunia

**Table 4: Showing mean of Dyspareunia**

BT Mean	Mean	DiffD	%	Wilcoxon rank test				
				SD	SEM	P	Z	Significance
0.350	AT 0.0500	0.3	85.71	BT 0.489	0.109	0.031	-2.449	S
				AT 0.224	0.0500	1.000	-1.000	NS
	FU 0.000	0.45	100	FU 0.000	0.000	0.016	-2.646	S

Initial mean score for Regularity of cycle was 0.350, which decreased to 0.0500 after treatment & further to 0.000 after follow-up. This reflects mean difference of 0.3 & 0.45, respectively, after treatment & follow-up, indicating improvements of 85.71% & 100%. Additionally, tests for statistical significance confirm that these results are statistically sig., with p-values of 0.031 & 0.016

#### 5. Shudharthava

**Table 5: Showing mean of attainment of Shudarthava Lakshana**

BT Mean	Mean	DiffD	%	Wilcoxon rank test				
				SD	SEM	P	Z	Significance
0.900	AT 0.000	0.900	100	BT 0.308	0.144	<0.001	-4.243	S
				AT 0.000	0.000	1.000	1.976	NS
	FU 0.000	0.900	100	FU 0.000	0.000	<0.001	-4.243	S


Initial mean score for Shuddha Artava Lakshana was 0.900, which decreased to 0.000 after treatment & further to 0.000 after follow-up. This reflects mean difference of 0.9, respectively, after treatment & follow-up, indicating improvements of 100%. Additionally, tests for statistical significance confirm that these results are statistically significant, with p-values of <0.001 demonstrating definite therapeutic benefit of treatment on Shuddha Artava Lakshana

#### Final Result

**Table 6: Table showing Final result**

Final Result	No. of Subjects	Percentage
Conceived	4	20
Improved	14	70
No Relief	2	10
Total	20	100

**No. of Subjects**



■ No Relief ■ Conceived ■ Improved

**Figure 1: Showing the Final Result**

Out of 20 patients, 4 patients conceived. There was significant improvement found is attaining *Shudharthava*.

## Discussion

Unexplained Infertility account for a significant portion of female infertility. As the patients included in the present study were of unexplained infertility, and notable effects on attaining *Shuddhartava Lakshana* were noted, which is very important for conception. While correlating to modern science, *Shuddhartava* ensures a well-nourished endometrial lining, making implantation more successful.

Ayurveda offers various treatment options for managing this condition (*Vandhytwa*), with *Panchakarma* being the primary treatment as it removes *Srothorodha* and maintains *Tridosha Sathmyata*. *Basti*, a unique procedure, serves multiple therapeutic purposes, including *Shodhana*, *Balakara*, *Sangrahaniya*, *Vayasthapana* and *Shukra Vardhana*. It is *Paramoushadha* for *Vata* predominant diseases, as *Pakwaashaya* is the main site of *Vata*. It is classified as *Niruha* and *Anuvāsana Basti*. It stimulates the Enteric Nervous System to regulate the HPO axis function.

*Dashamoola* drugs are *Vatakaphahara* and when processed with *Ksheera* acts on *Tridosha*. *Dashamoola* drugs contain chemical constituents which regulate the menstrual cycle by estrogenic effects and enhance chances of conception by providing protective environment to reproductive cells by antioxidant effect. *Raktachandana* has *Vrishya* properties. The Chemical composition of *Raktachandana* have phytoestrogenic effects, Anti-inflammatory properties and does hormonal regulation. *Apamarga* has properties like *Deepana*, *Kaphavatahara*.

The Chemical composition of *Apamarga* is helpful in fertility as its chemical constituents possess the Antioxidant properties which support ovarian function and balance hormones. The gastrointestinal tract consists a complex enteric nervous system (ENS) extending from the esophagus to the anus, with the sigmoid, rectal, and anal regions being more richly innervated by parasympathetic fibers that stimulate defecation reflexes. Absorption occurs through the gastrointestinal mucosa via active transport and passive diffusion, with the rectum's dense blood and lymphatic vessels allowing lipid-soluble substances to be readily absorbed. The active ingredients in *Basti* formulations are mainly water-soluble, and the hyperosmotic nature of *Niruha Basti* enhances the uptake of harmful substances. The gut acts as a sensory organ with neural, immune, and sensory cells that provide feedback to local regulatory systems and communicate with the central nervous system (CNS). *Basti* stimulates the ENS, potentially impacting the CNS and restoring physiological balance while targeting inflammatory substances with its anti-inflammatory components. Ingredients like honey and *Saindhava* generate action potentials, while the *Kalka* may induce colonic distention, triggering evacuatory reflexes and catecholamine release. Recent studies highlight the importance of gut-brain interactions in managing menstrual discomfort, as visceral afferent stimulation activates the HPA axis and autonomic nervous system, restoring neurotransmitter and hormone balance.

Also, Action of *Basti* in this study can be analyzed *Basti* action can be analyzed as; by fostering gut-brain communication, these interactions can alleviate symptoms associated with menstrual discomfort.

Hence, we can conclude the properties of *Dashamoola* drugs and *Sahacharadi Taila* along with the combination of *Raktachandana Yoga* collectively help in *Artava Dushti* and *Yonidosha* and thus help in *Vandhyatwa*.

## Conclusion

In conclusion, this study effectively highlights the combined therapeutic impact of *Dashamoola Ksheera Basti* and *Rakta Chandana Yoga* in managing female infertility.

*Vandhyatwa*, as established, should not be considered an isolated condition but rather the result of various *Yoni Vyapath* and *Arthava Dushti*, predominantly influenced by *Vatadushti*. Hence, normalizing *Vata Dosha* emerges as the central focus in infertility management.

The clinical use of *Sahacharadi Taila*, administered as *Matra Basti*, proved significantly beneficial due to its *Vatahara* properties and established indications for *Yoniroga*. Additionally, the combination of *Dashamoola* (noted for its *Vatakapahara* properties) and *Ksheera* (renowned as *Amritopama*) further enhanced therapeutic efficacy, emphasizing the relevance of *Dashamoola Ksheera Niruha Basti* as a preferred intervention.

*Rakta Chandana (Vrishya)* and *Apamarga (Vatahara)*, key components of the oral combination, demonstrated synergistic action in improving fertility parameters. The results revealed notable success, with four patients successfully conceiving, alongside substantial symptomatic relief in conditions such as dysmenorrhea, dyspareunia, and improvements in *Shudharthava*. Two patients achieved conception within the treatment duration, while two others conceived during the follow-up period.

Overall, this study underscores the efficacy of integrative Ayurvedic interventions in addressing female infertility, paving the way for further research to validate these findings and expand their clinical applicability.

## References

1. Dutta DC. Infertility. In: Konar H, editor. DC Dutta's textbook of gynecology. 6th ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013. p. 227 [Crossref][PubMed][Google Scholar]
2. SingleCare [Internet]. Infertility statistics; [cited 2025-03-30]. Available from: <https://www.singlecare.com/blog/news/infertility-statistics/> [Crossref][PubMed][Google Scholar]
3. Pandey J, editor. Harita Samhitha, Trutiyaasthana, Vandhyarogalakshana. Chapter 48, verse 1. Varanasi: Chaukambha Vishwabharati; 2010. p. 463 [Crossref][PubMed][Google Scholar]

4. Sharma HP. Commentary of Vidyotini Hindi on Kashyapasamhitha, Sutrasthana, Rogadhyaya. Chapter 27, verse 29. Varanasi: Chaukambha Sanskrit Series; 2009. p. 146 [Crossref][PubMed][Google Scholar]
  5. Acharya YT, editor. Commentary of Chakrapani on Charakasamhitha, Chikitsasthana; Yonivyapat Chikitsa Adhyaya. Chapter 30, verse 113. Varanasi: Chaukambha Sanskrit Series; 2013. p. 639 [Crossref][PubMed][Google Scholar]
  6. Acharya YT, editor. Commentary of Chakrapani on Charaka Samhitha, Siddhisthana; Kalpanasiddhi Adhyaya. Chapter 1, verse 40. Varanasi: Chaukambha Sanskrit Sansthan; 2015. p. 683 [Crossref][PubMed][Google Scholar]
  7. Acharya YT, editor. Commentary of Chakrapani on Charaka Samhitha, Siddhisthana; Kalpanasiddhi Adhyaya. Chapter 1, verse 29. Varanasi: Chaukambha Sanskrit Sansthan; 2015. p. 682 [Crossref][PubMed][Google Scholar]
  8. Matekar MV, Vijayran D. Sahachar (Barleria prionitis) - A literary review from Ayurvedic text and research articles. J Orient Res Madras. 2023 Jun;16-32. [Crossref][PubMed][Google Scholar]
  9. Acharya YT, editor. Commentary of Chakrapani on Charaka Samhitha of Agnivesha, Sutrasthana; Sneha Adhyaya. Chapter 13, verse 15. Varanasi: Chaukambha Sanskrit Sansthan; 2015. p. 82 [Crossref][PubMed][Google Scholar]
  10. Acharya YT, editor. Sushruta Samhita of Sushruta, Sutrasthana; Annapanavidhi Adhyaya. Chapter 46, verse 428. 1st ed. Varanasi: Chaukambha Orientalia; 2017. p. 244 [Crossref][PubMed][Google Scholar]
  11. KC. Bhavaprakasha Nighantu of Bhavamishra, Karpuradivarga. Chapter 2, verse 17. 1st ed. Varanasi: Chaukambha Vishwabharati; 2010. p. 182 [Crossref][PubMed][Google Scholar]
  12. Sharma GP. Kaiyadeva Nighantu of Pathyapathya Vibhodhaka, Aushadhivarga. Chapter 1, verse 1034. 1st ed. Varanasi: Chaukambha Orientalia; 1979. p. 267 [Crossref][PubMed][Google Scholar]
- Disclaimer / Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Journals and/or the editor(s). Journals and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.